Publicaciones (56) Publicaciones de Aintzane Asumendi Mallea

2024

  1. IPCC2023: Looking for translational opportunities by persevering in basic pigment cell research

    Pigment Cell and Melanoma Research, Vol. 37, Núm. 5, pp. 546-554

  2. Lipid fingerprint-based histology accurately classifies nevus, primary melanoma, and metastatic melanoma samples

    International Journal of Cancer, Vol. 154, Núm. 4, pp. 712-722

  3. PLGA-PEI nanoparticle covered with poly(I:C) for personalised cancer immunotherapy

    Drug Delivery and Translational Research, Vol. 14, Núm. 10, pp. 2788-2803

  4. Small extracellular vesicle-based human melanocyte and melanoma signature

    Pigment Cell and Melanoma Research, Vol. 37, Núm. 5, pp. 569-582

2023

  1. A Universal Antigen-Ranking Method to Design Personalized Vaccines Targeting Neoantigens against Melanoma

    Life, Vol. 13, Núm. 1

  2. Computational and Experimental Evaluation of the Immune Response of Neoantigens for Personalized Vaccine Design

    International Journal of Molecular Sciences, Vol. 24, Núm. 10

  3. Melanoma Clinical Decision Support System: An Artificial Intelligence-Based Tool to Diagnose and Predict Disease Outcome in Early-Stage Melanoma Patients

    Cancers, Vol. 15, Núm. 7

  4. Melanoma and Nevi Subtype Histopathological Characterization with Optical Coherence Tomography

    Life, Vol. 13, Núm. 3

  5. Pirin is a prognostic marker of human melanoma that dampens the proliferation of malignant cells by downregulating JARID1B/KDM5B expression

    Scientific Reports, Vol. 13, Núm. 1

  6. Zelula barneko zein jariatutako CEMIPek larruazaleko fibroblastoen mugikortasuna erregulatzen du

    Osasun zientziak: V. Ikergazte Nazioarteko Ikerteta Euskaraz. 2023eko maitzaren 17, 18 eta 19 Donostia, Euskal Herria.

2022

  1. Association of TYR SNP rs1042602 with Melanoma Risk and Prognosis

    Life, Vol. 12, Núm. 12

  2. Upregulated phospholipase D2 expression and activity is related to the metastatic properties of melanoma

    Oncology Letters, Vol. 23, Núm. 5

2021

  1. A uhplc-mass spectrometry view of human melanocytic cells uncovers potential lipid biomarkers of melanoma

    International Journal of Molecular Sciences, Vol. 22, Núm. 21

  2. Soluble pd-l1 is an independent prognostic factor in clear cell renal cell carcinoma

    Cancers, Vol. 13, Núm. 4, pp. 1-17

  3. The multifunctional role of SPANX-A/D protein subfamily in the promotion of pro-tumoural processes in human melanoma

    Scientific Reports, Vol. 11, Núm. 1

2020

  1. BRAF V600E mutational load as a prognosis biomarker in malignant melanoma

    PLoS ONE, Vol. 15, Núm. 3

  2. Innate lymphoid cells in the malignant melanoma microenvironment

    Cancers, Vol. 12, Núm. 11, pp. 1-27

  3. RKIP regulates differentiation-related features in melanocytic cells

    Cancers, Vol. 12, Núm. 6, pp. 1-22

  4. Serum markers improve current prediction of metastasis development in early-stage melanoma patients: a machine learning-based study

    Molecular Oncology, Vol. 14, Núm. 8, pp. 1705-1718

2019

  1. Altered expression of renin-angiotensin system receptors throughout colorectal adenoma-adenocarcinoma sequence

    International Journal of Medical Sciences, Vol. 16, Núm. 6, pp. 813-821